Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Envisia Therapeutics Inc.
DescriptionExtended-release formulation of travoprost developed using fully biodegradable particle replication in non-wetting templates (PRINT) technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationGlaucoma
Indication DetailsTreat bilateral ocular hypertension and early primary open-angle glaucoma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today